DENVER--(BUSINESS WIRE)--Ceragenix Pharmaceuticals, Inc.(“Ceragenix”) (OTCBB:CGXP), a medical device company focused on infectious disease and dermatology today announced that it has entered into an exclusive distribution and supply agreement (the “Agreement”) with Dávi II – Farmacêutica S.A., a Portuguese company, (“Dávi ”), to commercialize EpiCeram®, a topical cream for treating atopic dermatitis and other dry skin conditions in Europe (the “Territory”). The Agreement grants Dávi exclusivity in the Territory for the distribution and marketing of EpiCeram® via its own sales force as well as through partnering arrangements. Ceragenix will be responsible for the manufacturing and supply of the product. Dávi is also responsible for obtaining regulatory clearance to market EpiCeram® in the Territory. Financial terms were not disclosed.
